MedTrace Logo

Fenofibrate Versus Curcumin in Type 2 Diabetic Patients

NCT04528212 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-03-04

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of fenofibrate versus curcumin on glycemic status, lipids profile, hs-CRP, sirtuin-1 and fetuin-A in type 2 diabetic patients who are taking glimepiride.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Glimepiride Tablets

Glimepiride (4 mg) per Day

DRUG

glimepiride plus fenofibrate

Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day

DRUG

glimepiride plus curcumin

Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day

Sponsors & Collaborators

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass.Prof. · Damanhour University

  • Eman Nada, B. Pharm · Damanhour University

  • Haidy Abass, Ass.Prof. · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-11-30
Completion
2021-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04528212 on ClinicalTrials.gov